Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia
This clinical trial is focused on studying a type of blood cancer called Chronic Myelogenous Leukemia (CML), specifically in its early stage known as the chronic phase. The study is comparing two oral medications: Asciminib Hydrochloride and Nilotinib. Both medications are taken by mouth and are designed to help manage CML by targeting specific cancer cells. The purpose of the study is to evaluate how well patients tolerate these medications and how effective they are in treating CML.
Participants in the study will be randomly assigned to receive either Asciminib Hydrochloride or Nilotinib. The study will monitor how long patients can continue the treatment without stopping due to side effects. The trial will also look at how well the medications work in controlling the disease over time. Patients will be regularly assessed to track their response to the treatment and any side effects they may experience.
The study aims to provide valuable information about the safety and effectiveness of these treatments for people newly diagnosed with Chronic Myelogenous Leukemia in the chronic phase. The trial is expected to run for several years, allowing researchers to gather comprehensive data on the long-term outcomes of using these medications. Participants will receive regular check-ups and support throughout the study to ensure their well-being and to gather necessary information for the research.
1initial assessment
Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying the diagnosis of chronic myeloid leukemia in the chronic phase and ensuring the presence of the Philadelphia chromosome.
Laboratory tests are performed to check blood counts and organ function. These tests ensure that the body can handle the study medications.
2randomization
Participants are randomly assigned to receive either asciminib or nilotinib. This process is random to ensure unbiased results.
3medication administration
Participants take the assigned medication orally. The specific dosage and frequency are determined by the study protocol and are explained during the initial assessment.
The duration of medication administration continues throughout the study unless discontinued due to adverse effects.
4regular monitoring
Regular visits are scheduled to monitor health and response to the medication. These visits include physical examinations, blood tests, and other necessary assessments.
Monitoring helps track the effectiveness of the treatment and any side effects that may occur.
5evaluation of treatment response
The response to treatment is evaluated at various time points. This includes measuring the levels of the BCR::ABL1 gene, which is associated with the disease.
The goal is to achieve a significant reduction in this gene’s activity, indicating a positive response to treatment.
6completion of study
The study is estimated to conclude by March 2027. Participants will have a final assessment to evaluate overall health and treatment outcomes.
The results contribute to understanding the tolerability and effectiveness of the medications for future treatment strategies.
Who Can Join the Study?
You must sign a form agreeing to participate in the study.
You must be a male or female who is 18 years of age or older.
You must have been diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) within the last 3 months.
Your diagnosis of CML-CP must be confirmed by specific tests, including the presence of the Philadelphia (Ph) chromosome. If the Ph chromosome is not visible, another test called Fluorescence in situ Hybridization (FISH) should confirm it.
Your blood and bone marrow tests must show:
Less than 15% of certain immature blood cells called blasts.
Less than 30% of blasts plus another type of immature cell called promyelocytes.
Less than 20% of a type of white blood cell called basophils.
A platelet count of at least 100,000 per cubic millimeter.
No signs of leukemia outside the bone marrow, except for possible enlargement of the liver or spleen.
You must have evidence of a specific genetic marker called BCR::ABL1 transcript, which can be measured by a test called RQ-PCR.
Your overall health must be good, as measured by a scale called the Eastern Cooperative Oncology Group (ECOG) performance status, with a score of 0 or 1.
Your organs must be functioning well, with specific blood test results showing:
Total bilirubin less than 3 times the normal limit, unless you have a condition called Gilbert’s syndrome.
Creatinine clearance of at least 30 milliliters per minute, which measures kidney function.
Serum lipase levels within a safe range, which is an enzyme related to the pancreas.
Your blood levels of potassium, calcium, and magnesium must be within normal limits or corrected with supplements if needed. If you have mild to moderate kidney issues, these levels should still be normal or corrected.
Who Cannot Join the Study?
Patients who have been diagnosed with a type of blood cancer called Chronic Myeloid Leukemia in the Chronic Phase cannot participate if they have already received treatment for this condition.
Individuals who are not within the specified age range for the study cannot participate. The study is open to certain age groups, so those outside these groups are excluded.
Participants who are unable to follow the study procedures or take the study medication as required will not be able to join the trial.
People with other serious health conditions that might interfere with the study or put them at risk cannot participate.
Women who are pregnant or breastfeeding are not allowed to take part in the study.
Individuals who have a history of allergic reactions to the study medications or similar drugs are excluded.
Participants who are currently taking other medications that might interfere with the study treatment are not eligible.
Anyone who has participated in another clinical trial within a certain time frame before this study cannot join.
Individuals with a history of drug or alcohol abuse that might affect their ability to participate in the study are excluded.
Patients who have had a recent major surgery or are planning to have surgery during the study period cannot participate.
Asciminib is a medication being studied for its ability to treat patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in the Chronic Phase. It works by specifically targeting and inhibiting a protein that is involved in the growth of cancer cells, which may help to slow down or stop the progression of the disease.
Nilotinib is another medication used in the study for treating the same type of leukemia. It is designed to block certain proteins that promote the growth of cancer cells, thereby helping to control the disease. The study aims to compare the tolerability and effectiveness of nilotinib with asciminib in patients.
Chronic Myeloid Leukemia – Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the overproduction of immature white blood cells, known as myeloid cells. CML typically progresses through three phases: chronic, accelerated, and blast crisis. In the chronic phase, symptoms may be mild or absent, and the disease progresses slowly. As it advances to the accelerated phase, symptoms become more pronounced, and the number of abnormal cells increases. In the blast crisis phase, the disease behaves more like an acute leukemia, with rapid progression and severe symptoms.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Bulgaria 
Czechia 
France 
Germany 
Greece 
Hungary 
Italy 
Romania 
Slovakia 
The Netherlands 
